Item 8.01 Other Events.
On
The 037 Patent and the Provisional Patent Application described an invention that is directed to a method of preparing zinc-charged pancreatic enzymes, which is further directed to a method of treating cancer and inflammation using the zinc-charged pancreatic enzymes. Charging the pancreatic enzymes with zinc ions activate the pancreatic enzyme's anticancer and anti-inflammation properties and make the enzymes capable of being administered orally. It is observed that the zinc-charged pancreatic enzymes are able to induce apoptosia in various cancer cells without affecting the normal cells. The zinc-charged pancreatic enzymes have also been observed inducing apoptosis in trophoblasts and reducing inflammation in general.
Our study has revealed that amylase-Zn possesses multiple anticancer mechanisms. First, in additional to the induction of apoptosis, amylase-Zn reduced the expression of PD-L1 in cancer cell lines by 90%, suggesting that amylase-Zn may be used as an immunotherapy agent for cancer treatment. Secondly, amylase-Zn reduced the expression of c-Myc by 45%, which may inhibit tumor growth. Third, amylase-Zn inhibited the secretion of IL-6, IL-8 and TNF-alpha, suggesting that amylase-Zn may inhibit cancer metastasis.
In vitro, cell lines study showed that amylase-Zn has strong apoptosis-inducing
activity on various pancreatic cancer cell lines such as: BxPC-3,
--------------------------------------------------------------------------------
© Edgar Online, source